We are studying if adding Fianlimab to Cemiplimab and chemotherapy is safer and more effective for adults with early-stage non-small cell lung cancer that can be surgically removed. This trial will help us understand the best treatment options for these patients.
We are testing a new gene therapy for boys with Duchenne Muscular Dystrophy who can walk. The study aims to find the right dose and evaluate the therapy's safety and effectiveness compared to a placebo.
We are studying new treatment combinations for patients with advanced esophageal cancer who have already been treated with PD-1/PD-L1 therapies. The aim is to evaluate their safety and how well they work in shrinking tumors and improving survival.
We are studying whether a 6-week chemotherapy treatment before surgery helps older adults with resectable colon cancer live longer and stay disease-free. This trial aims to personalize treatment for patients aged 70 and older.
We are studying whether early intravenous omega-3 fatty acids can help reduce organ failure and mortality in patients with acute pancreatitis. This trial compares the effects of omega-3s to standard medical care.
We are studying new methods to monitor multiple myeloma in patients who have not yet been treated. This trial compares different treatment combinations, including a stem cell transplant, to see which is more effective.
We are studying a new treatment combining cell therapy and an antibody for children with early-stage type 1 diabetes. The goal is to see if this approach can help delay the onset of diabetes symptoms.
We are investigating how different doses of adenosine affect blood flow in the heart for healthy individuals and patients with coronary artery disease. This study aims to understand if the response varies based on health status.
We are studying whether steroid injections are more effective than saline injections and occupational therapy for painful thumb osteoarthritis. The goal is to improve pain, function, and overall quality of life.
We are testing a new drug, MP0533, for patients with acute myeloid leukemia or myelodysplastic syndrome. The study aims to evaluate its safety and how well it may work against these blood cancers.
We are testing whether chemotherapy before surgery improves outcomes for patients with high-risk retroperitoneal sarcoma. This study compares the effects of preoperative chemotherapy to surgery alone.
We are exploring whether tirzepatide can improve heart health by changing plaque composition and blood flow in people with obesity and coronary artery disease. This study compares tirzepatide to a placebo to assess its effects.
We are studying whether adding Epcoritamab to standard R-CHOP treatment helps people with newly diagnosed Diffuse Large B-Cell Lymphoma live longer without disease progression. This trial compares the new combination to R-CHOP alone.
We are examining how much ofatumumab is found in the breast milk of mothers with relapsing multiple sclerosis. This research will help us understand the safety and effects on breastfeeding infants.
We are studying the combination of EXL-01 and nivolumab for patients with advanced non-small cell lung cancer who have not responded to prior immunotherapy. The trial aims to evaluate how well this combination works and its safety.
We are studying the effects of capecitabine combined with pembrolizumab in patients with triple negative breast cancer after surgery and chemotherapy. This trial aims to see if this combination improves survival rates compared to standard treatments.
We are studying whether the immunotherapy dostarlimab can help patients with advanced non-colorectal and non-endometrial cancers live longer compared to standard treatments. This trial focuses on those with specific genetic markers in their tumors.
We are studying a new treatment combination for people with previously untreated advanced melanoma. The goal is to see if it helps patients live longer and have better outcomes compared to standard treatment.
We are studying a new treatment, ONC-392, to see if it helps patients with metastatic non-small cell lung cancer who have progressed on immunotherapy. The goal is to compare its effectiveness and safety against the standard treatment, docetaxel.
We are exploring whether a new imaging method can help visualize and measure healing in fistulas for patients with perianal Crohn’s disease. This study may also help predict how well treatments are working.